[PP.19.14] the Incidence of Dyslipidemia Among Hypertensive With and Without Diabetes

Sousa, A C; Jardim, Paulo César Brandão Veiga; Magalhães, Fabrício Galdino; Barroso, Weimar Sebba; Jardim, T.; Costa, Thiago Oliveira; Mikael, Luana de Rezende; Rodrigues, Renne; Ferreira, Verônica Reis; Souza, Haroldo Silva de; Moreira, Humberto Graner; Neiva, T.C.; Oliveira, CR; Sousa, Wátila de Moura; Sousa, A

doi:10.1097/01.hjh.0000492020.92361.fb

Journal of Hypertension

2016

DOI: 10.1097/01.hjh.0000492020.92361.fb

|View full text |Cite

[PP.19.14] the Incidence of Dyslipidemia Among Hypertensive With and Without Diabetes

A C Sousa

Paulo César Brandão Veiga Jardim

Fabrício Galdino Magalhães

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dyslipidemia increases the risk of cardiovascular disease (CVD), which is the second leading cause of death worldwide. 1,2 Statin is the first-line treatment, 3 and adding other lipid-lowering agents is recommended when the serum lipid level is not controlled. 4 Ezetimibe is frequently combined with a statin for its synergistic effect of inhibiting cholesterol absorption.…”

mentioning

confidence: 99%

Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and Telmisartan

Huh

Lee

Lee³

et al. 2021

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

To evaluate the pharmacokinetic interactions among rosuvastatin, ezetimibe, and telmisartan, a randomized, open-label, 3period, 6-sequence crossover study was conducted in healthy subjects. Subjects received one of the following treatments once daily for 7 days in each period with a 1-week washout: a fixed-dose combination of ezetimibe/rosuvastatin 10/20 mg, telmisartan 80 mg, combination therapy of ezetimibe/rosuvastatin 10/20 mg, or telmisartan 80 mg. Blood samples were collected up to 24 hours postdose at steady state. Geometric mean ratios (GMRs) and their 90% confidence intervals (CIs) of the combination therapy to monotherapy for the maximum plasma concentration (C max,ss ), and the area under the time-concentration curve within a dosing interval at steady state (AUC tau,ss ) were estimated. Among the 36 randomized subjects, 31 subjects completed the study. The GMRs and 90%CIs of C max,ss and AUC tau,ss of total ezetimibe were not significantly altered. The C max,ss of free ezetimibe was increased (

show abstract

mentioning

confidence: 99%

Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and Telmisartan

Huh

Lee

Lee³

et al. 2021

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

[PP.19.14] the Incidence of Dyslipidemia Among Hypertensive With and Without Diabetes

Cited by 1 publication

References 0 publications

Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and Telmisartan

Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and Telmisartan

Contact Info

Product

Resources

About